According to the Schizophrenia<\/a> and Related Disorders Alliance of America, approximately 3.5 million people in the United States are diagnosed with schizophrenia (n.d.), and it is one of the leading causes of disability. In practice, patients may present with delusions, hallucinations, disorganized thinking, disorganized or abnormal motor behavior, as well as other negative symptoms that can be disabling for these individuals. Not only are these symptoms one of the most challenging symptom clusters you will encounter, many are associated with other disorders, such as depression, bipolar disorder, and disorders on the schizophrenia spectrum. As a psychiatric nurse practitioner, you must understand the underlying neurobiology of these symptoms to select appropriate therapies and improve outcomes for patients.<\/span>\u00a0<\/span><\/p>\n This week, as you examine antipsychotic therapies, you explore the assessment and treatment of patients with psychosis and schizophrenia. You also consider ethical and legal implications of these therapies.<\/span>\u00a0<\/span><\/p>\n Schizophrenia and Related Disorders Alliance of America. (n.d.).\u202f<\/span>About\u202f schizophrenia<\/span><\/i>.https:\/\/sardaa.org\/resources\/about-schizophrenia\/#:~:text=Quick%20Facts%20About%20Schizophrenia.%20Schizophrenia%20can%20be%20found,is%20one%20of%20the%20leading%20causes%20of%20disability<\/a><\/span>\u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n Required Readings<\/span><\/b>\u202f(click to expand\/reduce)<\/span><\/a>\u00a0<\/span><\/p>\n Freudenreich, O., Goff, D. C., & Henderson, D. C. (2016). Antipsychotic drugs. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), <\/span>Massachusetts General Hospital psychopharmacology and neurotherapeutics<\/span><\/i>\u202f(pp. 72\u201385). Elsevier.<\/span>\u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n American Psychiatric Association. (2019). <\/span>Practice guideline for the treatment of patients with schizophrenia<\/span><\/i>. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Practice\/Clinical%20Practice%20Guidelines\/APA-Draft-Schizophrenia-Treatment-Guideline.pdf<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Clozapine REMS. (2015). <\/span>Clozapine REMS: The single shared system for clozapine<\/span><\/i>. https:\/\/www.clozapinerems.com\/CpmgClozapineUI\/rems\/pdf\/resources\/Clozapine_REMS_A_Guide_for_Healthcare_Providers.pdf<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Funk, M. C., Beach, S. R., Bostwick, J. R., Celano, C. M., Hasnain, M., Pandurangi, A., Khandai, A., Taylor, A., Levenson, J. L., Riba, M., & Kovacs, R. J. (2018). <\/span>Resource document on QTc prolongation and psychotropic medications<\/span><\/i>. American Psychiatric Association. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Directories\/Library-and-Archive\/resource_documents\/Resource-Document-2018-QTc-Prolongation-and-Psychotropic-Med.pdf<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. <\/span>Schizophrenia Bulletin, 13<\/span><\/i>(2), 261\u2013276.\u202fhttps:\/\/doi.org\/10.1093\/schbul\/13.2.261<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Levenson, J. C., Kay, D. B., & Buysse, D. J. (2015). The pathophysiology of insomnia. <\/span>Chest, 147<\/span><\/i>(4), 1179\u20131192. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4388122\/<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n McClellan, J. & Stock. S. (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. <\/span>Journal of the American Academy of Child and Adolescent Psychiatry, 52<\/span><\/i>(9), 976\u2013990. https:\/\/www.jaacap.org\/article\/S0890-8567(09)62600-9\/pdf<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Naber, D., & Lambert, M. (2009). The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians. <\/span>CNS Drugs, 23<\/span><\/i>(8), 649\u2013659. https:\/\/doi.org\/10.2165\/00023210-200923080-00002<\/span><\/a>\u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n Antipsychotic agents, also called neuroleptic or major tranquilizers, are used primarily to treat schizophrenia. Schizophrenia is characterized primarily by a clear sensory but marked thinking disturbance. Second-generation\/ Atypical antipsychotics are widely used due to their broad spectrum of receptor activity since they affect Serotonin, dopamine, and GABA neurotransmitters (de Miranda et al., 2020). Besides, they are better at alleviating negative symptoms and cognitive dysfunction than typical antipsychotics. The purpose of this assignment is to develop a study guide for an antipsychotic agent.<\/p>\n Quetiapine, whose brand name goes by Seroquel, is used in treating schizophrenia. It is FDA-approved for treating schizophrenia, Bipolar disorder, and major depressive disorder<\/a> (MDD) as an adjunctive treatment (de Miranda et al., 2020).<\/p>\n The non-FDA uses of Seroquel include the treatment of generalized anxiety disorder (GAD), Alcohol Dependence, and Insomnia.<\/p>\n Seroquel is an antipsychotic<\/a> under second-generation antipsychotics.<\/p>\nReference:<\/span><\/h2>\n
Learning Objectives<\/span>\u00a0<\/span><\/h2>\n
Students will:<\/span><\/b>\u00a0<\/span><\/h3>\n
\n
\n
Learning Resources<\/span>\u00a0<\/span><\/h2>\n
A Sample Answer For the Assignment: NURS 6630 Study Guide for Medication Treatment Schizophrenia Spectrum and Other Psychosis Disorders<\/strong><\/h2>\n
Title: NURS 6630 Study Guide for Medication Treatment Schizophrenia Spectrum and Other Psychosis Disorders<\/strong><\/h2>\n
Drug Description<\/strong><\/h2>\n
Non-FDA uses<\/strong><\/h2>\n
\n
Drug classification<\/strong><\/h2>\n
![\"NURS](\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2023\/04\/NURS-6630-Study-Guide-for-Medication-Treatment-Schizophrenia-Spectrum-and-Other-Psychosis-Disorders-300x124.png\")